- Moderna announced that their COVID vaccine tested on 8 people was safe and helped those people produce antibodies to neutralize COVID. The second phase involving 600 people is set to begin soon.
The biotech tested three dosing regimens of its coronavirus vaccine in healthy adults ages 18-55. Across all three groups, participants began showing began showing antibodies against Covid-19 by day 15 after receiving one dose. The presence of antibodies could indicate immunity.
In one group, patients received two doses of the coronavirus vaccine. At day 43, two weeks after receiving the second dose, the level of antibodies in participants' blood was similar to levels for patients who already recovered from Covid-19.
A second group received two higher doses of the coronavirus vaccine. At day 43, the antibodies in their blood exceeded that of recovered Covid-19 patients. The third group of patients received a single higher dose. Samples aren't yet available for those participants.
"These interim Phase 1 data, while early, demonstrate that vaccination with (the vaccine called) mRNA-1273 elicits an immune response of the magnitude caused by natural infection starting with a dose as low as 25 micrograms," Moderna Chief Scientific Officer Tal Zaks said in a written statement.
No comments:
Post a Comment